Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.

Publication date: Jan 09, 2020

Uveal melanoma (UM) is a rare and malignant intraocular tumour with a dismal prognosis. Despite a good control of the primary tumour by radiation or surgery, up to 50% of patients subsequently develop metastasis for which no efficient treatment is yet available.

To identify therapeutic opportunities, we performed an in vitro screen of 30 combinations of different inhibitors of pathways that are dysregulated in UM. Effects of drug combinations on viability, cell cycle and apoptosis were assessed in eight UM cell lines. The best synergistic combinations were further evaluated in six UM patient-derived xenografts (PDXs).

We demonstrated that the Bcl-2/X/W inhibitor (ABT263) sensitised the UM cell lines to other inhibitors, mainly to mammalian target of rapamycin (mTOR), mitogen-activated protein kinase kinase (MEK) and murine double minute 2 (MDM2) inhibitors. mTOR (RAD001) and MEK1/2 (trametinib) inhibitors were efficient as single agents, but their combinations with ABT263 displayed no synergism in UM PDXs. In contrast, the combination of ABT263 with MDM2 inhibitor (HDM201) showed a trend for a synergistic effect.

We showed that inhibition of Bcl-2/X/W sensitised the UM cell lines to other treatments encouraging investigation of the underlying mechanisms. Furthermore, our findings highlighted Bcl-2/X/W and MDM2 co-inhibition as a promising strategy in UM.

Open Access PDF

Decaudin, D., Frisch Dit Leitz, E., Nemati, F., Tarin, M., Naguez, A., Zerara, M., Marande, B., Vivet-Noguer, R., Halilovic, E., Fabre, C., Jochemsen, A., Roman-Roman, S., and Alsafadi, S. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. 25445. 2020 Eur J Cancer (126):

Concepts Keywords
Apoptosis MTOR
Inhibitor Mdm2
Kinase Navitoclax
Malignant Bcl-2
MDM2 Chloroarenes
MEK Programmed cell death
Metastasis Apoptosis
Mitogen Melanoma
MTOR Oncogenes
Murine Chemical compounds
Prognosis Branches of biology
Radiation Surgery
Rapamycin Radiation
Synergism Tumour
Synergistic Metastasis
Tumour Sirolimus
Uveal Melanoma Drug screening
Xenografts Apoptosis
Radiation

Semantics

Type Source Name
disease MESH uveal melanoma
disease MESH metastasis
pathway KEGG Cell cycle
pathway KEGG Apoptosis
drug DRUGBANK Sirolimus
drug DRUGBANK Trametinib

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *